ANNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Annexon Inc (ANNX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown some positive price movement recently and has potential upside based on analyst ratings, the technical indicators and financial performance do not strongly support a buy decision. Additionally, there are no significant trading signals or news catalysts to justify immediate action.
The MACD histogram is below 0 and negatively contracting, indicating a bearish trend. RSI is neutral at 61.707, and moving averages are converging, suggesting indecision in price movement. The stock is trading near its resistance level (R1: 5.339), which could limit further short-term upside.
Analyst Daniil Gataulin initiated coverage with a Buy rating and a $16 price target, citing commercial potential in key therapeutic areas. Stock trend analysis suggests a 70% chance of moderate gains in the next month.
No significant news or event-driven catalysts in the past week. Hedge funds and insiders are neutral, with no notable trading trends. Financial performance remains weak with no revenue and negative net income.
In Q3 2025, the company reported no revenue, a net loss of $54.92 million (improved by 57.71% YoY), and an EPS of -0.37 (up 48% YoY). While losses are narrowing, the company remains unprofitable with no revenue growth.
Chardan analyst initiated a Buy rating with a $16 price target, citing potential in complement C1q inhibitors for Guillain-Barre syndrome and geographic atrophy. Additional upside potential exists in Huntington's disease.
